Five years after my lymphoma diagnosis, life looks normal on the outside; however, the fear of recurrence and the reality of ...

During a live event, Priyanka Pophali, MD, MBBS, discussed CAR T-cell therapy referrals, timing, and challenges in relapsed ...

The FDA has approved Monjuvi (tafasitamab) for relapsed follicular lymphoma, offering hope with improved progression-free survival in combination therapy.

T-follicular helper (TFH) lymphoma is a blood cancer subgroup that continues to demonstrate a generally poor prognosis, with no standard treatment established to date. Although specific genetic ...

Follicular lymphoma -- typically a slow-growing or indolent form of non-Hodgkin lymphoma that arises from B lymphocytes -- ...

Treatments for follicular lymphoma are often prescribed in combination to give you the best outcome or to treat your cancer after other therapies haven’t worked. Find out what combination ...

We conducted a retrospective review of 181 PET scans performed in 117 nonselected consecutive patients with FL treated in our institution from 2002 to 2007. Patients who underwent PET examination ...

For follicular lymphoma, SUVmax thresholds to identify HT were generally higher than those for Richter’s transformation, suggesting the need for alternative diagnostic approaches in these cases. When ...

CURE® spoke with an expert about follicular lymphoma, a disease that is still considered incurable. There have been a number of advancements in the treatment of follicular lymphoma in 2024.

Investigators sought to determine the impact of early histological transformation of follicular lymphoma on patient outcomes and developed a novel risk prediction tool.

There’s no one-size-fits-all treatment for follicular lymphoma. The best treatment for you depends on many factors.

Can you explain the mechanism of action of epcoritamab-bysp and what sets it apart from existing R/R follicular lymphoma treatments? Epcoritamab is a CD20/CD3 bispecific antibody.